Development of a transferrin receptor-targeting HVJ-E vector.
The development of more effective cancer treatments is anticipated. Tumor-targeted drug delivery is an important strategy in cancer therapy. We have developed an HVJ (hemagglutinating virus of Japan; Sendai virus) envelope (HVJ-E) vector using inactivated Sendai virus. The HVJ-E vector has been observed to target a number of cell lines since its hemagglutinin-neuraminidase (HN) protein recognizes the sialic acids of host cells. Thus, to reduce non-specific binding of the HVJ-E vector, we eliminated HN protein using HN-specific short interfering RNA (siRNA). Then, to further increase its tumor-targeting ability, we constructed HN-depleted HVJ containing the F-transferrin chimeric protein. The modified vectors containing Q-dots demonstrated 32-fold greater tumor-targeting efficiency than wild-type HVJ-E.
Shimbo
Takashi
T
Division of Gene Therapy Science, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan.
Kawachi
Masako
M
Saga
Kotaro
K
Fujita
Hiroshi
H
Yamazaki
Takehiko
T
Tamai
Katsuto
K
Kaneda
Yasufumi
Y
D000818:Animals; D002460:Cell Line; D016503:Drug Delivery Systems / Q000379:methods; D018390:Gene Targeting / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics*; D006367:HeLa Cells; D006801:Humans; D007668:Kidney / Q000378:metabolism*; D051379:Mice; D008819:Mice, Nude; D029082:Sendai virus / Q000235:genetics*; D014162:Transfection / Q000379:methods*; D014168:Transferrin / Q000235:genetics* / Q000378:metabolism*
D014168:Transferrin